Clinical Trials Browser

Phase 1/2 × Lymphoma × tomivosertib × Clear all

NCT02937675 2020-11-02

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies

Phase 1/2 Terminated

Lymphoma